Study of bone scans for advanced prostate cancer treatment
Part of Cancer, Hormones & metabolism clinical trials.
This trial is testing how well treatments for advanced prostate cancer that has spread to the bones can be seen on scans. It may help doctors find better ways to measure if the cancer is responding to treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have prostate cancer that no longer responds to hormone therapy.
- You have cancer that has spread to one or more bones.
- You are expected to live longer than 6 months.
- You do not have any other active cancer besides prostate cancer.
- You are willing to undergo special scans (MRI, CT, or bone scan) and do not have any reason that would make these scans unsafe for you.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new radioactive drug designed to target and destroy prostate cancer cells. It is for men whose cancer has continued to grow despite hormone therapy and other treatments like enzalutamide or abiraterone.
This research study tests a new MRI imaging method to measure how much radiation reaches your bone marrow during a standard prostate cancer treatment called Lu-177 PSMA therapy. The goal is to help doctors better understand and protect bone marrow during this treatment.
This trial tests whether adding radiation therapy to the prostate and cancer spread sites helps men whose prostate cancer has spread to bones but isn't responding well to standard hormone treatments. You'd be eligible if your PSA level (a cancer marker) stays high after six months of dual hormone therapy.
This trial studies special MRI images to learn how well they can find prostate cancer before treatment. It may help doctors choose better next steps during biopsy or during active surveillance.
This Phase 2 trial tests a radiation-focused approach for people with newly diagnosed (de novo) prostate cancer that has spread to a small number of spots, especially in bone. It aims to see how well the treatment controls the cancer while keeping side effects manageable.
This trial tests a new radioactive treatment, [225Ac]Ac-FL-020, for men with metastatic castration-resistant prostate cancer (mCRPC) that has gotten worse despite other treatments. It's for those who have had at least one prior hormone therapy or chemotherapy.
Hear when a new Castration-resistant Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.